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Abstract: Alzheimer’s disease is the most common form of neurodegenerative diseases in humans, characterized by the 
progressive accumulation and aggregation of amyloid-? peptides (A?) in brain regions subserving memory and cognition. 
These 39-43 amino acids long peptides are generated by the sequential proteolytic cleavages of the amyloid-? precursor 
protein (APP) by ?- and ?-secretases, with the latter being the founding member of a new class of intramembrane-cleaving 
proteases (I-CliPs) characterized by their intramembranous catalytic residues hydrolyzing the peptide bonds within the 
transmembrane regions of their respective substrates. These proteases include the S2P family of metalloproteases, the 
Rhomboid family of serine proteases, and two aspartyl proteases: the signal peptide peptidase (SPP) and ?-secretase. In 
sharp contrast to Rhomboid and SPP that function as a single component, ?-secretase is a multi-component protease with 
complex assembly, maturation and activation processes. Recently, two low-resolution three-dimensional structures of ?-
secretase and three high-resolution structures of the GlpG rhomboid protease have been obtained almost simultaneously 
by different laboratories. Although these proteases are unrelated by sequence or evolution, they seem to share common 
functional and structural mechanisms explaining how they catalyze intramembrane proteolysis. Indeed, a water-containing 
chamber in the catalytic cores of both ?-secretase and GlpG rhomboid provides the hydrophilic environment required for 
proteolysis and a lateral gating mechanism controls substrate access to the active site. The studies that have identified and 
characterized the structural determinants critical for the assembly and activity of the ?-secretase complex are reviewed 
here. 
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INTRODUCTION 
Alzheimer’s disease (AD) is the most common form of 
neurodegenerative diseases in humans, leading to nerve cell 
death and tissue loss throughout the brain, therefore impair-
ing memory, reasoning and behavior and leading ultimately 
to complete social dependence and death. During the past 
two decades, a working hypothesis known as the ‘amyloid-? 
cascade hypothesis’ has been developed suggesting that the 
progressive accumulation/oligomerization/aggregation of 
amyloid-? peptides (A?) in brain regions subserving mem-
ory and cognition, including the frontal cortex and the hip-
pocampus, is the primary cause of neurodegeneration and 
cell death in AD [1]. Compelling genetic evidence support-
ing this hypothesis came in 1991, when missense mutations 
in the gene that encodes the A? precursor protein (APP) 
were found to cause AD in certain families [2-4]. 
A? is formed from amyloid-? precursor protein (APP) 
through two protease activities [5]. First, the membrane teth-
ered aspartyl protease ?-secretase (BACE 1, [6]) cleaves 
APP at the A? N-terminus (? cleavage site), resulting in a 
soluble form of APP (sAPP?; Fig. (1)) and a 99-residue 
(~12kDa) C-terminal fragment (C99; Fig. (1)). This C-
terminal fragment undergoes subsequent processing by ?-
secretase (? cleavage site) resulting in the formation of A?  
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peptides of various lengths (39-43 amino-acid residues), with 
the two primary forms being the 40- and 42- amino acid 
variants, A?40 and A?42. Although A?42 accounts for only 
10% of total A? secreted from cells (A?40 predominants), 
A?42 is the major protein component of amyloid plaques [7-
9] and aggregates much more rapidly than A?40 in vitro 
[10]. An alternative non-amyloidogenic processing pathway 
of APP molecules involves its cleavage within the A? region 
(? cleavage site), by another member of the secretase family, 
the ?-secretase metalloproteases ADAM10 and tumor necro-
sis factor ? (TNF-?)-converting enzyme (TACE/ADAM17) 
[11, 12]. Cleavage by ?-secretase precludes the formation of 
A? and results in the release of a soluble form of APP 
(sAPP?; Fig. (1)) and membrane retention of a 83-residue 
(~10kDa) C-terminal fragment (C83) (Fig. (1)). Subsequent 
cleavage of C83 by ?-secretase results in an N-terminally 
truncated and non-toxic A? protein of 3 kDa (p3; Fig. (1); 
[13]). In addition to APP processing, ?-secretase has been 
implicated in intramembranous cleavage of a whole set of 
type I membrane proteins, including Notch, the growth fac-
tor dependent receptor Erb-B4, the cell adhesion molecules 
N-cadherin, E-cadherin, CD44, and the neurotrophin co-
receptor p75 (for a review, see [14]).  
In cells, ?-secretase activity is associated with a high mo-
lecular weight multiprotein complex that is composed at 
least of four integral membrane proteins, presenilin (PS, 9 
TMDs), Nicastrin (NCT, 1 TMD), PEN-2 (2 TMDs), and 
APH-1 (7 TMDs), with PS (and two conserved and crucial  
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intra-membrane aspartate residues) constituting the catalytic 
component [16] and the other 3 proteins acting as essential 
cofactors and/or scaffold proteins necessary for the assembly 
and activation of the complex [17, 18]. NCT has further been 
reported to be involved in the recognition and binding of 
substrates [19] whereas PEN-2 triggers the endoproteolysis 
of PS into PS-NTF and PS-CTF during the maturation/ 
activation of the complex [17]. Indeed, studies performed in 
Drosophilia and mammalian cells have shown that NCT, 
APH-1 and PEN-2 stabilize and promote the increased for-
mation of mature PS N- and C-terminal fragments and ?-
secretase activity, suggesting that PS heterodimers (NTF/ 
CTF), NCT, APH-1 and PEN-2 are both necessary and suffi-
cient for ?-secretase activity [17, 18]. The reconstitution of ?-
secretase activity in S. cerevisiae (which lacks ?-secretase) 
by expressing just these four components further supports 
this conclusion [20]. The subsequent high-grade purification 
of the human ?-secretase complex from CHO cells that sta-
bly overexpress human PS1, APH-1 and PEN-2 (designated 
?-30 cells) accompanied by a detailed mass spectral analysis 
of all the proteins found in the catalytically active fraction 
provided further compelling evidence that PS NTF/CTF, 
NCT, APH-1 and PEN-2 are the components of active ?-
secretase [21]. Because understanding the workings of ?-
secretase is important for both biomedical research (because 
of its role in the generation of A?, ?-secretase has emerged 
as a key therapeutic target for AD) and basic biology (i.e. 
cell signaling and stem cells differentiation), structural in-
formation of the protease complex is needed to gain func-



















Fig. (1). APP processing and the production of the amyloid-?  peptides. APP is synthesized as a type I transmembrane protein which 
initially undergoes cleavage at either ?- or ?-secretase sites to release large ectodomains, designated sAPP? or sAPP?, respectively. Ecto-
domain shedding leaves membrane-embedded fragments, C99 (99-residue C-terminal APP fragment) or C83 (83-residue C-terminal APP 
fragment), which are substrates for ?-secretase cleavage. Proteolysis of C99 by ?-secretase promotes the extracellular release of the amyloi-
dogenic fragments (A?, toxic pathway) whereas proteolysis of C83 by ?-secretase generates an N-terminally truncated and non- toxic A? 
protein of 3 kDa (P3, non-toxic pathway). Evidence suggests that the progressive accumulation/oligomerization/aggregation of A? in brain 
regions subserving memory and cognition is the primary cause of neurodegeneration in Alzheimer’s disease. Proteolysis of C99 and C83 by 
?-secretase also releases the APP intracellular domain (AICD). Following association with the adaptor protein Fe65 and nuclear transloca-
tion, AICD is able to suppress the expression of the major apoE/lipoprotein receptor LRP1 by binding directly to its promoter [15]. Thus, 
APP processing is also involved in the regulation of brain apoE (a major genetic determinant of AD) and cholesterol metabolism. 
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(EM) and single particle image analysis on the enzyme puri-
fied from the ?-30 cells revealed the presence of a low-
density interior chamber and apical and basal pores that 
could allow the entry of water molecules (required to ac-
complish peptide bond hydrolysis) and their sequestration 
from the lipid surround by the proteinaceous microenviron-
ment provided by the 19 transmembrane domains [22]. This 
first 3D structure of the complex also provided plausible 
explanations about how ?-secretase releases its cleavage 
products into distinct subcellular compartments [22]. Despite 
this progress, the exact spatial organization and functional 
contribution of each ?-secretase subunit to the enzymatic 
activity remain largely unknown.  
?-Secretase is the founding member of an emerging class 
of intramembrane-cleaving proteases (I-CliPs) that includes 
site 2 protease (S2P) cleaving membrane-anchored transcrip-
tion factors involved in cholesterol biosynthesis [23], Rhom-
boids responsible for releasing epidermal growth factor in 
Drosophila [24] and signal peptide peptidase (SPP), a PS-
like protein that requires two conserved aspartates to cleave 
remnant signal peptides left in the membrane after genera-
tion by signal peptidase [25]. Like ?-secretase, S2P, Rhom-
boid, and SPP all hydrolyze their respective substrates within 
their TM regions, and the residues responsible for catalysis 
are either intramembranous or at the predicted membrane-
cytosol interfaces of the proteases. Recently, atomic struc-
tures of the GlpG rhomboid protease from Escherichia coli 
were reported [26-28]. Although GlpG rhomboid protease 
from E. coli and ?-secretase are unrelated by sequence or 
evolution, they seem to share common functional and struc-
tural mechanisms explaining how they catalyze intramem-
brane proteolysis.  
The Minimal Set of Components to Constitute ?-Secretase 
Complex 
1. Presenilin 1 and Presenilin 2: Catalytic Components of 
the ?  -Secretase Complex 
In 1995, independent groups identified genetic linkage 
and mutations within PSEN1 (chromosome 14, 14q24.3) and 
PSEN2 (chromosome 1, 1q42.2) genes in several early onset 
familial Alzheimer’s disease (FAD) kindreds [29-31]. So far, 








=196010&CFTOKEN=37631420) have been identified to 
cause FAD. PSEN1 and PSEN2 encode 467 and 448 amino 
acid-long polytopic transmembrane proteins, termed preseni-
lin 1 (PS1) and presenilin 2 (PS2), respectively. The se-
quence identity between these two highly conserved proteins 
is 67% [29].  
Transmembrane Topology of Presenilin 1 
Until now, several different models for the transmem-
brane domain (TMD) topology of PS1 have been proposed, 
including a 6-TMD model [32], a 7-TMD model (reviewed 
in [33], and a 8-TMD model topology with the N- and C- 
termini, and a hydrophilic loop domain between TMD6 and 
TMD7 facing the cytosol, which has been, until very re-
cently, widely accepted by the Alzheimer’s community [34-
36]. However, five very recent computational and experi-
mental studies have demonstrated that the N-terminal do-
main of PS1 is cytosolic, the C-terminal domain of PS1 is 
extracytoplasmic, and that PS1 adopts a 9-TMD topology 
[37-41] as depicted in Fig. (2). Further evidence supporting 
the latter model comes from the observation that signal pep-
tide peptidase (SPP), one of the five PS homologues identi-
fied in the human genome based on sequence conservation, 
adopts a 9-TMD topology, although with an opposite mem-
brane orientation [42-44].  
Domains of PS1 Critical for the Assembly and/or the Activ-
ity of the ?  -Secretase Complex 
“TMD1” Motif  
A large deletion in PS1-NTF that removes the two first 
TMDs has been reported by two independent studies to 
cause reduced endoproteolysis and reduced ?-secretase activ-
ity [45, 46]. Brunkan et al. have used a mutational analysis 
approach and rescue assays in cultured PS1/PS2 knockout 
fibroblasts to investigate the sequence requirements in 
TMD1 of PS1 necessary to support both ?-secretase and pre-
senilinase (endoproteolysis of PS into PS-NTF and PS-CTF) 
activities [47]. This study allowed for the identification of 
two distinct domains within TMD1 of PS1: (1) an N-ter- 
minal domain (residues 87 to 90) that is important for ?-
secretase activity but not for presenilinase activity, and (2) a 
C-terminal domain (residues 95-98) that is essential for both 
enzymatic activities. Importantly, photoactivatable transi-
tion-state analog inhibitors targeting the active site of ? -
secretase failed to bind to PS1 containing the V96F muta-
tion, supporting the hypothesis that the residues 95-98 are 
required for proper active site conformation [47].  
“NF” Motif (TMD4)  
We recently demonstrated a physical interaction between 
PS1-NTF and PEN-2 by promoting the partial dissociation of 
the ?-secretase complex using dodecyl ?-D-maltoside 
(DDM), a mild detergent [48]. The DDM-resistant interac-
tions identified in the dissociated complexes likely reflect the 
physical interactions existing in the active ?-secretase com-
plex. Moreover, the use of an antibody targeting the extreme 
C-terminus of PS1 revealed that PS1-holoprotein can associ-
ate with PEN-2 in a manner independent of the other ?-
secretase components NCT and APH-1, further supporting a 
direct physical interaction between PS1 and PEN-2 [48]. 
Two independent groups recently used the so called “Swap 
method” (replacement of specific TMDs of PS1 with TMDs 
of unrelated membrane proteins) for the analysis of the indi-
vidual roles of PS1 TMDs for binding with PEN-2 [49, 50]. 
Both studies have identified a highly conserved consensus 
motif (XWNFGX, residues 202-207 in human PS1) among 
multiple organisms required and sufficient for PS1:PEN-2 
interactions. Indeed, chimeric mutant PS1 swapped at TMD4 
[49, 50] and PS1 NFGV to YIIL mutant [50] lack ?-secretase 
activity because of loss of interaction with PEN-2. Collec-
tively, both studies have demonstrated that the NF motif in 
TMD4 of PS1 is critical for binding with PEN-2, thus pro-
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moting PS1 endoproteolysis and activation of ?-secretase. 
Furthermore, the same studies have shown that TMDs 1, 2, 
3, 5 and 6 of PS1 are dispensable for interaction with PEN-2, 
but critical for ?-secretase activity [49, 50]. 
Exon 9 Hydrophobic Domain (between TMD6 & TMD7)  
Human PS1 is synthesized as a 43 kDa polypeptide that 
undergoes highly regulated endoproteolysis to generate sta-
ble 27 kDa N-terminal (PS1-NTF) and 16 kDa C-terminal 
(PS1-CTF) fragments in a 1:1 stoichiometry [51]. This en-
doproteolytic cleavage occurs within the large cytoplasmic 
loop connecting TMD 6 and 7, between amino acid residues 
M292 and V293 of human PS1 (or M298 and V299 of hu-
man PS2) in a highly hydrophobic domain known to be de-
leted in a PS1 variant that lacks amino acid residues 290-319 
following a point mutation upstream of a splice acceptor site 
resulting in an in-frame deletion of exon 9 (PS1?E9) [51-
55]. This mutation has been identified in the PS1 gene in 
families with early onset AD and the corresponding PS1?E9 
protein is not subject to endoproteolytic cleavage [51, 52]. 
Specific mutations of the endoproteolytic cleavage sites of 
human PS1 (single mutants M292D and M292E, and double 
mutant M292D/V293K) and human PS2 (M298D/V299A) 
block or greatly reduce PS endoproteolysis [54-56]. Whether 
these mutations affecting PS endoproteolysis also affect di-
rectly ?-secretase activity remains unclear, but strong evi-
dence supports the hypothesis that this endoproteolytic event 
is a critical step in the assembly and activation of ?-secretase 
(discussed below).  
Aspartate 257 (TMD6) and Aspartate 385 (TMD7): The 
Core of an Aspartyl Catalytic Site 
Different Calpain cystein protease inhibitors including 
MDL28170 (carbobenzoxyl-Val-Phe-alaninal), Calpain I, 
MG 132 (carbobenzoxyl-Leu-Leu-leucinal) and Calpeptin 
(carbobenzoxyl-Leu-norleucinal) have first been reported to 
reduce the amounts of A? and P3 secreted from different cell 
lines transfected with APP (carrying the Swedish mutations 
or not), while C-terminal APP intermediates accumulated 
within the cells, thus suggesting a direct inhibition of ?-
secretase [57-60]. Moreover, these peptide aldehyde cystein 
protease inhibitors did not affect A?40 and A?42 with the 
same potency, suggesting two pharmacologically distinct 
proteolytic activities: a ?(40)-secretase and a ?(42)-secretase 
generating A?40 and A?42, respectively [59, 60]. It has also 
been reported that Pepstatin A, an inhibitor of the lysosomal 
aspartyl proteinase cathepsin D, inhibited the cleavage of 
APP-based substrates resulting in A? production [61, 62]. 
The latter data suggested that cathepsin D itself or a cathep-
sin D-like activity maybe ?-secretase – with the first hy-
pothesis being rapidly ruled out by the observation that A? 

















Fig. (2). The minimal set of components of the ?-secretase complex. Topological models of human PS1, NCT, APH-1 and PEN-2 (left) 
showing the domains which have been experimentally determined to be critical for the assembly and/or activity of the ?-secretase complex 
(rigth). The transmembrane domains (TMDs) are shown as cylinders, stars represent the two catalytic aspartates (D257 and D385) in human 
PS1, and asterisks represent TMDs with N- or C-terminal regions immediately adjacent to them.  
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of hippocampal neurons derived from cathepsin D knock out 
mice [63]. The first pharmacological evidence supporting an 
aspartyl protease mechanism for ?-secretase came with the 
finding that peptide analogues specifically designed based on 
the Ala713-Thr714 APP cleavage site leading to A?42 (sub-
strate-based difluoro ketones that mimic an intermediate in 
aspartyl-protease catalysis) inhibit A? production in both 
cell-based and cell-free microsomal ?-secretase activity as-
says [64, 65]. Moreover, these inhibitors were not effective 
against calpain (cystein protease) but did inhibit cathepsin D 
(aspartyl protease), further supporting that ?-secretase is an 
aspartyl protease [65]. Next, two conserved transmembrane 
aspartate residues in PS1 have been identified to be essential 
for ?-secretase activity and PS endoproteolysis [16]. Indeed, 
mutation of Asp 257 (D257A in TMD6) or Asp 385 (D385A 
in TMD7) of human PS1 substantially reduce A? production 
and increase the amounts of the APP-based substrates of ?-
secretase [16]. Moreover, biotinylated transition-state ana-
logs designed to interact specifically with the catalytic aspar-
tates of ?-secretase bind specifically and directly to PS1 (and 
PS2)-NTF and PS1 (and PS2)-CTF [66, 67]. Finally, PS-
deficient (PS1-/- PS2 -/- double knockout) embryonic stem 
cells are completely devoid of ?-secretase activity [68, 69]. 
When taken together, these findings support the notion that 
PS forms the catalytic center of ?-secretase with two trans-
membrane aspartate residues (Asp 257 and Asp 385 in hu-
man PS1, and Asp 263 and Asp 366 in human PS2) forming 
the catalytic dyad of the enzyme.  
“GxGD” Motif (TMD7)  
PS, signal peptide peptidase (SPP) and presenilin ho-
mologs/SPP-like proteins (PSHs/SPPL) contain a highly 
conserved GxGD sequence motif (residues 382-385 in hu-
man PS1) including the C-terminal active site aspartate 
(TMD7) [70, 71]. The glycine 384, which is immediately 
adjacent to the critical aspartate at residue 385 of PS1, is 
required for PS1 endoproteolysis and ?-secretase activity 
[70]. Recently, Yamasaki et al. reported that the PS1 L383F 
mutant (affecting substrate identification as described below) 
was endoproteolytically processed and allowed maturation of 
NCT, suggesting that this residue does not play an important 
role in the assembly of the complex [71]. 
TMD8  
Shiraishi et al. reconstituted recently ?-secretase activity 
by co-expressing C-terminally truncated PS1 (lacking ?-
secretase activity), the corresponding PS1 C-terminal deleted 
fragment and PS cofactors NCT, APH-1 and PEN-2 in 
PS1/PS2 double deficient MEFs [72]. In this study, the ex-
pression of PS1-C68 (PS1 C-terminal 68 residues containing 
TMD8 and TMD9) rescued a defect in the ?-secretase activ-
ity of PS1?C66 (PS1 lacking the C-terminal 66 residues con-
taining TMD8 and TMD9). Similarly, the expression of PS1-
C37 (PS1 C-terminal 37 residues containing TMD9) rescued 
a defect in the ?-secretase activity of PS1?C37 (PS1 lacking 
the C-terminal 37 residues containing TMD9). However, the 
expression of PS1-C37 (containing TMD9) failed to rescue a 
defect in the ?-secretase activity and assembly of PS1?C66 
(lacking TMD8 and TMD9), demonstrating that TMD8 is 
critical for both the assembly and the activity of ?-secretase 
[72]. 
“PAL” Motif (TMD9)  
Wang and al. recently investigated the molecular mecha-
nism by which the essential proline-alanine-leucine (PAL) 
motif in PS1 (residues 433-435 in human PS1) contributes to 
?-secretase activity [73, 74]. Single point mutations to this 
motif (P433L, A434D and L435R) completely abolish ?-
secretase activity [73, 75]. Originally proposed to be impor-
tant for the assembly and stabilization of the ?-secretase 
complex (a hypothesis that was not consistent with the fact 
that this motif is conserved in SPP, which unlike PS1, does 
not require cofactors for activity), Kaether et al. and Wang et 
al. later demonstrated that this motif was not involved in the 
?-secretase complex formation [73]. Indeed, the P433L PS1 
mutations did not affect ?-components stability, trafficking 
and incorporation into the active high molecular weight 
complex [74]. Nevertheless, mutations at this motif com-
pletely abolish binding to a transition-state analog inhibitor 
of ?-secretase, supporting the hypothesis that this motif, like 
the TMD1, is important for the proteolytic mechanism of ?-
secretase [74]. Consistent with an enzymatic function of the 
PAL motif, the same sequence is also essential for SPP ac-
tivity. Interestingly, the PAL sequence is located within the 
final TMD in the 9-TMD topological revised model, as ex-
pected for such a motif to be directly involved in an intram-
embrane-cleaving activity [74].  
2. Nicastrin: Stabilizer of the ?-Secretase Complex & Sub-
strate Receptor 
NCT was the second member of ?-secretase to be identi-
fied (year 2000), initially detected through a genetic screen 
in C. elegans [76] and isolated later biochemically from 
mammalian cells following partial affinity purification using 
a PS1-directed antibody [77]. Human NCT is a 709 amino 
acid residues long single-pass type I membrane protein (Fig. 
(2)) that possesses an N-terminal predicted signal peptide, a 
large N-terminal hydrophilic ectodomain with 16 potential 
glycosylation sites, one hydrophobic TMD and a short hy-
drophilic C-terminus of 20 amino-acid residues [77]. NCT 
exists in cells under three principal forms: (1) the unglycosy-
lated, nascent protein (~70-80 kDa), (2) the “immature” N-
linked isoform (iNCT; ~110 kDa) that is mainly located 
within the ER (endoglycosidase-H-sensitive glycosylation 
pattern) and is not associated with active ?-secretase, and (3) 
the “mature” N-linked isoform (mNCT; ~130-150 kDa) that 
is formed after entering the Golgi apparatus (complex glyco-
sylation pattern) and trans-Golgi network (sialylation) [78-
82] and is found only in the active complex.  
Domains of Nicastrin Critical for the Assembly and/or the 
Activity of the ?-Secretase Complex 
Research has focused on the domains of PS that are criti-
cal for ?-secretase activity (see above), but less is known 
about the domains of NCT that are essential for the assembly 
and/or the activity of ?-secretase. Fibroblast cells isolated 
from two independently generated NCT KO mouse strains 
have been used to investigate the functions of NCT within 
the ?-secretase complex [83-85]. Reduced matured PS frag-
ments (PS-NTF & PS-CTF) have been observed in these 
three different studies. Moreover, down-regulation of NCT 
in different cell lines by small interfering RNA (siRNA)  
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revealed a reduction of PS fragments [17, 84, 86-88]. When 
taken together, those data support an essential role for NCT 
in maintaining the stability of the complex.  
NCT Ectodomain Including the Conserved “DYIGS” Motif  
Three domains (residues 306-360, 419-458, and 625-662 
in human NCT) with significant sequence conservation have 
been identified in orthologous NCT genes (from different 
species) including Human, Mouse, Drosophila melanogaster 
and C. elegans [77]. Within the first conserved domain, all 
four proteins contained the motif DYIGS (residues 336-340 
in human NCT) which is apparently a PS binding domain 
[77]. Indeed, deletion of the DYIGS motif caused a signifi-
cant reduction in the NCT/PS1 interaction, as well as a re-
duction in both A?42 and A?40 secretion in HEK293 cells 
stably overexpressing APP with Swedish mutation and the 
mutant NCTs [77, 89]. Murphy et al. confirmed that muta-
tions in DYIGS motif (amino-acid deletions of residues 312-
340 or 312-369) resulted in the loss of function phenotype 
with respect to ?-secretase processing of APP-based sub-
strates [90]. Intriguingly, mutants of the DYIGS motif (DY-
IGS to AAIGS [77] or D336A/Y337A [89]) caused a signifi-
cant increase in A? secretion [77, 89]. In an attempt to iden-
tify the functionally important domains of NCT, Shirotani et 
al. generated a set of deletions and point mutations within 
the NCT ectodomain and probed the corresponding cDNAs 
for their faculty to restore ?-secretase assembly and activity 
in a HEK293 cell line in which endogenous NCT expression 
was stably knocked-down by RNAi [86, 87]. All investigated 
deletions within the ectodomain (including the DYIGS mo-
tif) as well as mutations in (G339A) or close to (E333Q) the 
DYIGS motif failed to restore those functions, suggesting an 
important role of the entire ectodomain in ?-secretase assem-
bly and activity [86, 87]. Two conserved residues (S632 and 
W648) in the juxtamembrane region of the NCT ectodomain 
have also been identified as essential residues for ?-secretase 
complex formation and activity [91]. In contrast, the cyto-
plasmic tail of NCT was found to be dispensable for ?-
secretase complex assembly and activity [92].  
The loss of function phenotype observed in most of the 
NCT mutants of the DYIGS motif described above can be 
explained by the recent finding that NCT functions as a ?-
secretase-substrate receptor that recognizes the short N-
terminal stubs generated by ectodomain shedding of type-I 
membrane proteins [19]. Indeed, Shah and colleagues found 
that the NCT ectodomain (but not the cytoplasmic and TMD 
regions) physically interacts with APP- and Notch-based 
substrates in co-immunoprecipitation experiments performed 
with Triton X-100 membrane extracts from baculovirus in-
fected Sf9 cells expressing different NCT constructs plus 
APP-C99 or N100, a Notch-based fragment resulting form 
TACE cleavage [19]. Next, NCT harboring a deletion within 
its ectodomain (NCT?312-340 including the DYIGS motif) 
or a mutation close to the DYIGS motif (NCT-E333A) failed 
to restore ?-secretase activity in NCT-/- fibroblasts and failed 
to interact physically with APP-C99/C83 in the same cells 
[19]. Supporting this observation, the NCT ectodomain in-
cluding the residues 306-360 (the most conserved sequence 
amongst NCT orthologs) shows sequence similarity to a pep-
tidase family including aminopeptidases characterized by a 
glutamate residue in the active site that interacts directly with 
the substrate [93-95]. Based on this observation and using 
known aminopeptidase structures as a model, Shah et al. 
postulate that the highly conserved glutamate residue at posi-
tion 333 of NCT is positioned in an analogous substrate-
binding pocket within ?-secretase [19]. When taken together, 
these data demonstrate that a substrate binding site that is 
evolutionarily derived from a peptidase and including the 
DYIGS motif as well as the proximal glutamate residue at 
position 333 resides in the ectodomain of NCT. 
The TMD of NCT 
The TMD of NCT is required for the interaction with ?-
secretase complex components and for ?-secretase activity 
[92, 96]. To avoid the misfolding phenotype often associated 
with introducing deletions or mutations in glycosylated and 
disulfide bonded proteins [97] (such as NCT), Morais et al. 
developed a strategy based on the finding that C. elegans 
NCT failed to associate with human ?-secretase components 
[96]. They produced chimeras between human NCT and C. 
elegans NCT and examined their ability to interact with hu-
man ?-secretase components as judged by co-immunopreci- 
pitation. The authors found that the TMD of NCT as well as 
regions immediately adjacent to it (amino-acid residues 620-
709 of hNCT) play important roles in mediating pro-
tein:protein interactions between ?-secretase components as 
well as ?-secretase activity [96]. A sequential deletion analy-
sis further indicated that the N-terminal one-third of the NCT 
TMD is sufficient for the assembly of NCT into the ?-
secretase complex but also that the remaining C-terminal 
portion contributes to some extend to ?-secretase formation 
[92]. Moreover, a helical wheel projection of the NCT TMD 
revealed a hydrophilic patch which seems to be essential for 
the assembly within a functional ?-secretase complex [92]. 
When taken together, these data demonstrate that the TMD 
of NCT is important for both the assembly and the activity of 
?-secretase. 
3. Anterior Pharynx Defective (APH-1) 
In 2002, two independent but very similar genetic screens 
in C. elegans have revealed two additional PS and NCT co-
factors, APH-1 and PEN-2 (Fig. (2)) required for processing 
of PS into PS-NTF and PS-CTF heterodimers and for ?-
secretase activity [98, 99]. In C. elegans, the Notch signaling 
pathway is required for the development of the anterior half 
of the pharynx, and embryos defective in this requirement 
have an Aph (anterior pharynx) defective phenotype [76]. 
Worms that are defective in both PS genes (hop-1 and sel-
12) display all the hallmarks of Notch signaling defects in-
cluding maternal-effect embryonic lethality and germline 
sterility. In this screen, Francis et al. mutagenized single sel-
12 mutants or single hop-1 mutants (which are partially 
compromised for PS function, fully viable and fertile), and 
screened for mutants that display the Notch-like sterility 
phenotype seen in the double hop-1 and sel-12 mutants [99]. 
Two homologues of Aph-1 were identified, Aph-1a (mapped 
to chromosome I) and Aph-1b (mapped to chromosome 15) 
that at the genetic level interact with hop-1 and sel-12. At the 
protein levels, APH-1a exists in two C-terminal splice forms, 
the 247-amino acid splice variant APH-1aS and the 265-
amino acid splice variant APH-1aL which are identical ex-
cept at the C-terminus [99-101]. Human APH-1a and the  
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257-amino acid long APH-1b share 50% sequence homolo-
gies [100, 101]. Whereas APH-1a is the principal APH-1 
isoform present in ?-secretase complexes [102-104], the 
three different human APH-1 variants are able to form dis-
tinct active ?-secretase complexes [105, 106]. No penetrant 
mutations in the genes encoding Aph-1a and Aph-1b have 
been linked with the rare cases of familial AD [107]. 
Transmembrane Topology of APH-1 
Hydropathy plot analysis by the Kyte-Doolittle method 
shows that APH-1 proteins are largely hydrophobic, with a 
common pattern of seven hydrophobic regions that are pre-
dicted to be membrane-spanning regions [98, 108]. The ori-
entation with regard to luminal and cytosolic compartments 
has been investigated by Fortna et al. and using different 
experimental approaches [108]. Immunofluorescence mi-
croscopy performed under various and selective permeabili-
zation conditions of the plasma membrane strongly supports 
a model in which the C-terminus of APH-1 faces the cytoso-
lic space [108]. Furthermore, the method of glycosylation-
scanning mutagenesis (proteins containing this motif will be 
glycosylated only if the sequence is located within an ER 
luminally exposed region) revealed that the N-terminal do-
main as well as the predicted loops 2, 4, and 6 were glycosy-
lated, but not loops 1, 3, and 5. When taken together, these 
experiments offer a seven TMD model for the topology of 
APH-1 in which the N-terminus faces the ER lumen and the 
C-terminus resides in the cytosolic space (Fig. (2); [108]). 
Domains of APH-1 Critical for the Assembly and/or the 
Activity of the ?-Secretase Complex 
The “GXXXG” Motif: An Important Determinant in Trans-
membrane Helix:Helix Interactions  
The conserved Gly122, Gly126 and Gly130 in the APH-1 
family of proteins (TMD 4 of mammalian APH-1aL) have 
been identified as critical for ?-secretase assembly and activ-
ity [109-111]. These glycine residues are part of the GXXXG 
motif (where X represents any amino acid), generally ac-
cepted as a major motif in transmembrane helix:helix protein 
interactions [112, 113]. Consistent with this function, muta-
tions of Gly122, Gly126 and Gly130 in the GXXXG motif 
prevent the stable association of APH-1aL with PS and NCT, 
suggesting that APH-1 is a major docking site for the assem-
bly and consequently for the activation of ?-secretase [109]. 
Similar results were found in Drosophila S2 cells by using an 
RNAi-based complementation assay [110]. Further support-
ing the function of APH-1, Saito and colleagues recently 
identified a novel 216 amino acid splice variant of human 
APH-1b which lacks the normal exon 4 (APH-1b?4) and 
consequently the GXXXG motif described above [114]. Con-
sistent with the function of the GXXXG motif, APH-1b?4 
was less stable than APH-1b and APH-1b?4 was stabilized 
by NCT [114]. When taken together, the results described 
above indicate that the GXXXG transmembrane motif is es-
sential for the stability of the APH-1 protein, the assembly of 
the ?-secretase complex as well as the activity of ?-secretase. 
4. Presenilin Enhancer-2 (PEN-2)  
PEN-2 was detected in 2002 through two independent 
but very similar genetic screens in C. elegans [98, 99]. The 
corresponding human gene is located on chromosome 19 and 
encodes a 101 amino acid residues long protein. Downregu-
lation of PEN-2 expression in different cell lines by small 
interfering RNAs (siRNA) abolishes the endoproteolysis of 
PS (associated with a significant accumulation of full-length 
PS) and ?-secretase activity, whereas overexpression of 
PEN-2 promotes the cleavage of PS, indicating an important 
role for PEN-2 in PS-NTF and-CTF heterodimer formation 
[17, 115-117]. Recently, Pen-2 exons and nearby intronic 
regions were analyzed for the presence of mutations and/or 
polymorphisms in an Italian population sample of 140 famil-
ial AD patients, 256 sporadic AD patients, and 253 cogni-
tively normal elderly people as control group [118]. Scan-
ning the gene revealed the PEN-2 D90N very rare missense 
mutation in a patient with familial AD – however, the patho-
genic role of this mutation is not clear as preliminary data 
point to no influence of this mutation on APP processing and 
A?42 production [118].  
Transmembrane Topology of PEN-2 
The PEN-2 proteins identified in different species includ-
ing human, mouse, Drosophila, C. elegans and zebrafish 
show high sequence similarity throughout their length, con-
tain two predicted TMDs, and lack a signal peptide as well 
as any previously described and characterized conserved 
protein motifs [99]. The membrane topology of human PEN-
2 has been investigated by Crystal et al. using three different 
and complementary biochemical approaches: glycosylation-
scanning mutagenesis (used by Fortna et al. to support a 
model for the membrane topology of APH-1, see above), 
immunofluorescence microscopy as well as a protease pro-
tection assay using selective permeabilization conditions of 
the plasma membrane [119]. Based on their results, the 
authors came to a conclusion that PEN-2 spans the mem-
brane twice (thus confirming the two predicted TMDs), with 
the N- and C-termini facing the ER lumen and the hydro-
philic loop facing the cytosolic space (Fig. (2); [119]).  
Domains of PEN-2 Critical for the Assembly and/or the 
Activity of the ?-Secretase Complex 
The TMD1 of PEN-2 
The TMD1 of PEN-2 is critical for PS endoproteolysis 
and ?-secretase activity. The “Swap method” (replacement of 
PEN-2 TMDs with TMDs of sterol regulatory element bind-
ing protein 1 (SREBP-1)) was used for the analysis of the 
individual roles of PEN-2 TMDs for PS endoproteolysis and 
?-secretase activity [120]. The replacement of TMD2 of 
PEN-2 with the TMD1 from SREBP-1 was fully functional 
whereas the replacement of TMD1 of PEN-2 with the TMD2 
from SREBP-1 failed to trigger PS endoproteolysis [120]. 
This loss of function was further rescued by the replacement 
of the two-thirds of the SREBP-1 TMD2 with the two-thirds 
of the TMD1 of PEN-2 [120]. When taken together, these 
data suggest that the two-thirds of the TMD1 of PEN-2 are 
functionally important (in contrast to the TMD2 of PEN-2) 
for PS endoproteolysis and ?-secretase activity. 
The C-Terminal Highly Conserved DYLSF Motif of PEN-2 
The C-terminal highly conserved DYLSF motif of PEN-2 
is required for the stabilization of PS1 fragments (NTF & 
CTF). To define the PEN-2 functional domains, Prokop et al. 
initiated a structure-function analysis of PEN-2 using a 
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HEK293 cell line in which PEN-2 expression is stably 
knocked down by RNAi – loss of PEN-2 function (associ-
ated with reduced PS fragments and accumulation of PS-
holoprotein) can thus be assayed by functional complemen-
tation [121]. Steric alterations of the C-terminus of PEN-2 by 
the addition of a C-terminal myc-hexahistidine tag or by a C-
terminal truncation of 17 amino-acid residues did not allow 
the rescue of the defect in ?-secretase maturation, suggesting 
that the C-terminal domain of PEN-2 is a functionally criti-
cal domain [121]. In addition, alteration of the C-terminus of 
PEN-2 caused a selective instability of the PS1 heterodimers 
that underwent proteasomal degradation, supporting a criti-
cal role of the C-terminus of PEN-2 in the stabilization of the 
PS fragments and consequently in the assembly and activa-
tion of the complex [121]. The hydrophilic C-terminus and 
more specifically the amino acid residues 90-101 of PEN-2 
are conserved during evolution with the possibility to be 
functionally important [122]. Indeed, intensive mutation 
analysis within this domain revealed that the C-terminus of 
PEN-2 and more specifically the highly conserved DYLSF 
motif at residues 90-94 is important for the physical interac-
tion of PEN-2 to PS (thus stabilizing the PS fragments) and 
the maturation and activation of ?-secretase [122]. Consistent 
with these findings, two deletions in the N-terminal region 
(?3-9 and ?10-16), two in the loop between TMD1 and 
TMD2 (?40-46 and ?52-60) and two in the C-terminal re-
gion (?85-92 and ?93-100) had no or very little effects on 
the endoproteolysis of PS1 and ?-secretase activity in con-
trast to the deletion of the whole C-terminal region (?85-
101, including the conserved DYLSF motif at residues 90-
94), further supporting the critical function of the C-terminal 
hydrophilic region of PEN-2 for ?-secretase activity [120, 
123]. The overall DYLSF motif is the critical functional de-
terminant of PEN-2 as individual D90A and F94A mutations 
are functionally tolerated [123]. 
Assembly and Activation in the Secretory Pathway of the 
?-Secretase Complex (Fig. (3)) 
The glycosylation pattern of NCT and its conversion 
from an immature to a mature form within the secretory 
pathway has been extensively used to investigate the assem-
bly and trafficking of the ?-secretase complex in different 
cell lines (including CHO, HEK293, N2a, mouse embryonic 
fibroblasts and neurons). Basically, newly synthesized mam-
malian proteins are co-translationally modified in the ER by 
the addition of 14 oligosaccharide units, including 9 mannose 
residues, 3 glucose residues and 2 N-acetylglucosamine resi- 
dues (= N-linked glycosylation) [124]. In the medial/trans-
Golgi compartments, 6 of the mannose residues can be re-
placed with complex sugars including N-acetylglucosamine, 
galactose, sialic acid, fucose or chondroitin sulfate glycosa-
minoglycans [124]. The nature of such post-translational 
modifications of NCT has been addressed by taking advan-
tage of the differential susceptibility of glycoproteins to en-
zymes targeting specific post-translational modifications. 
First, digestion of iNCT and mNCT with PNGase F (peptide-
N-glucosidase F), an enzyme that cleaves all N-linked (but 
not O-linked) glycans regardless of complexity decreases the 
size of NCT to a size corresponding to the unglycosylated, 
nascent 70-80 kDa protein [80-82, 125]. Combined with the 
observation that (1) treatment with enzymes that cleave all 
O-linked (but not N-linked) glycans did not affect SDS-
PAGE mobility of iNCT and mNCT [80-82], and (2) lectins 
specific for N- glycans, in contrast to lectins specific for O-
glycans, do bind to iNCT and mNCT [81, 82], these results 
demonstrate that NCT is modified by N- but no O-linked 
glycosylation. Endoglycosidase-H (Endo-ß-N-acetylglucos- 
aminidase H, Endo-H) is a highly specific endoglycosidase 
cleaving asparagine-linked mannose rich oligosaccharides, 
but not highly processed complex oligosaccharides from gly- 
coproteins. Thus, glycoproteins within the ER and cis-Golgi 
compartments are Endo-H sensitive whereas complex glyco-
proteins within the medial- and trans-Golgi and later com-
partments (endosomes and plasma membrane) are Endo-H 
resistant. Consequently, Endo-H was used to differentiate the 
two forms of NCT, iNCT and mNCT [80-82, 125]. Collec-
tively, treatments with Endo-H revealed that a majority of 
mNCT is Endo-H resistant [80-82, 125] whereas iNCT is 
Endo-H sensitive [80-82, 125], demonstrating that iNCT and 
mNCT are located in different cell compartments: ER and 
cis-Golgi for iNCT and medial-Golgi, trans-Golgi and later 
compartments for mNCT. Velocity sedimentation and sub-
cellular fractionation of cells in iodixanol gradient further 
support the subcellular localization of iNCT and mNCT. 
Indeed, iNCT was primarily found in ER-enriched fractions 
whereas mNCT was found in Golgi-enriched fractions [80, 
81]. 
1. The iNCT/APH-1 Subcomplex: Early Formation in the 
Endoplasmic Reticulum 
We and others proposed that the assembly of the ?-secre- 
tase complex involves the early formation in the ER of an 
intermediate complex (= subcomplex) of APH-1 and the 
“immature” N-linked isoform of NCT (iNCT; 110 kDa) that 
is not associated with active ?-secretase [48, 87, 117]. In-
deed, the analysis under non-denaturing conditions using 
native gel electrophoresis (BN-PAGE) of ?-secretase com-
ponents solubilized from CHO and HEK293 cells revealed a 
subcomplex of 140 kDa which was immunoreactive for NCT 
and APH-1 but not for PS-heterodimers or PEN-2 [117]. The 
size of this subcomplex is consistent with the predicted size 
of iNCT (110 KDa) plus APH-1 (20 kDa). Further support-
ing a specific interaction between iNCT and APH-1, co-
immunoprecipitations experiments (co-IP) in multiple cell 
lines using antibodies against ectopically expressed as well 
as endogenous APH-1 revealed a selective association be-
tween those two proteins [117]. In working towards purifica-
tion of the ?-secretase complex, we expanded our analysis of 
detergents that keep the complex together and maintain ac-
tivity [48]. During this process, we identified one detergent 
(dodecyl-?-D maltoside, DDM) that, in contrast to 1% digi-
tonin, dissociated endogenous and overexpressed active ?-
secretase complexes into two major partial inactive com-
plexes, one containing PS1-NTF and PEN-2 and the other 
containing mNCT and APH-1 (as characterized by Blue na-
tive BN-PAGE combined with a second dimension using 
SDS-PAGE in order to break apart these partial complexes) 
[48]. The DDM-resistant interactions between PS1-NTF and 
PEN-2 and between mNCT and APH-1 likely reflect the 
physical interactions that exist in the active ?-secretase com-
plex. Assuming that the physical interactions revealed in the  
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DDM-dependent dissociated complexes reflect the order of 
assembly of the complex (strong interactions that do not re-
quire additional ?-secretase members would correspond to 
direct and specific interactions), our findings would suggest 
that the DDM-resistant mNCT:APH-1 complex reflects the 
iNCT:APH-1 subcomplex generated early during the assem-
bly of ?-secretase. In another study, three different mutations 
within conserved amino acid residues within the ectodomain 
of NCT caused the accumulation (in HEK293 cells) of iNCT 
variants which selectively bound to APH-1, independently to 
PS and PEN-2 [87]. Whether APH-1 stabilizes the unglyco-
sylated, nascent protein (80 kDa), and allows its glycosyla-
tion in the ER or whether the post-translational modification 
of the nascent NCT to iNCT is required for its interaction 
with APH-1 remains unknown. When taken together, these 
data demonstrate that APH-1 and iNCT form a stable inter-
mediate in the ER that would likely serve as a scaffold for 
the binding of PS and/or PEN-2 during the assembly of the 
active ?-secretase complex. 
2. The iNCT/APH-1/PS-Holoprotein Subcomplex 
Evidence exists that PS holoprotein then binds to the 
iNCT/APH-1 subcomplex to form a second intermediate, 
prior to the addition of PEN-2 and full complex maturation. 
First, PS is required for the trafficking of NCT to the Golgi 
apparatus [80, 82]. Indeed, the complete absence of PS in 
PS1-/- PS2-/- double knock out MEFs promotes the accumu-
lation of an Endo-H sensitive iNCT [80, 82]. Immunocyto-
chemical experiments performed on the same PS1-/- PS2-/- 
MEFs further revealed that the accumulated iNCT was 
largely located in the ER, suggesting that NCT needs to as-
sociate with PS to leave the ER [82]. Next, velocity method 
to fractionate subcellular organelles on continuous iodixanol 
gradients revealed a high degree of co-localization in CHO 
cells and WT MEFs of iNCT with PS1 holoprotein in ER 
enriched fractions and mNCT with PS heterodimers in the 
Golgi-enriched vesicle fractions [80, 81]. This supports the 
localization of immature PS (PS-holoprotein) and mature PS 
(PS heterodimers) to different cellular compartments and 
consequently an early association between iNCT and PS-
holoprotein. In support of this, we found that DDM-depen- 
dent dissociation of endogenous and overexpressed active ?-
secretase complexes generated a minor inactive complex 
containing mNCT, APH-1, and PS1-CTF as characterized by 
Blue native BN-PAGE combined with a second dimension 
using SDS-PAGE [48]. The NCT “DYIGS” motif (residues 
336-340 of human NCT) has further been proposed to be a 
PS binding domain [77] whereas the APH-1 “GXXXG” motif 
has been proposed to be both a PS and/or NCT binding do-
main [109-111], thus supporting possible physical interac-
tions between NCT and PS, and between APH-1 and PS 
and/or NCT, respectively. Finally, knock-down experiments 
using siRNAs directed against APH-1 and NCT reduced the 
formation of PS heterodimers without the stable accumula-
tion of PS-holoprotein observed in cells with down-regulated 
PEN-2. This observation suggests that (1) APH-1 and NCT 
could be involved in the stabilization of PS-holoprotein and 
(2) that APH-1, NCT and PS-holoprotein stabilize each 
other, independently of PEN-2. When taken together, these 
results support the existence of a subcomplex containing 
iNCT/APH-1/PS-holoprotein that has never been detected 
under physiological conditions, probably due to the very 
short half-life (1-2 hours) of PS-holoproteins when com-
pared to that for PS-heterodimers (> 24 hours) [53] and their 
rapid endoproteolysis into PS-NTF and PS-CTF fragments.  
3. The PEN-2 Dependent Maturation of PS Holoprotein 
The endoproteolytic activity that cleaves PS-holoprotein 
into PS-NTF and PS-CTF fragments has the characteristics 
of an aspartyl protease and most ?-secretase inhibitors block 
PS endoproteolysis, supporting the hypothesis that PS endo-
proteolysis is an autocatalytic event [126, 127]. A model for 
this autocatalytic endoproteolytic processing of PS has been 
recently reported in which the same ?-secretase active site 
within PS (D257 and D385 of human PS1) that cleaves APP- 
or Notch-based substrates also cleaves and activates PS itself 
[56]. In this model, the hydrophobic domain that contains the 
site of endoproteolysis is membrane-embedded (in a close 
proximity to TMD 6 and TMD 7), thus occluding the active 
site in the conformation adapted by a PS holoprotein – a hy-
pothesis that is supported by the observation that PS holo-
protein is not associated with active ?-secretase, except for 
the FAD PS1?E9 variant which lacks the PS endoproteolytic 
site but triggers ?-secretase activity. Next, the association of 
PS-holoprotein with ?-secretase would likely trigger a con-
formational change allowing the PS active site to cleave the 
E9 hydrophobic domain between the residues M292 and 
V293, resulting in the withdrawal of the hydrophobic do-
main around the active site residues that consequently be-
comes accessible for cleavage of ?-secretase substrates. Con-
sistent with this model, evidence suggests that the associa-
tion of PEN-2 to the trimeric iNCT/APH-1/PS-holoprotein 
subcomplex triggers the conformational change (in PS-
holoprotein?) promoting the endoproteolytic cleavage of PS-
holoprotein and consequently the activation of ?-secretase 
(depicted in Fig. (3)). First, knock-down experiments using 
siRNAs directed against PEN-2 lead (1) to reduced PS het-
erodimers, mNCT, active and stable ?-secretase complex, 
and (2) to the stable accumulation of PS-holoprotein [17, 
115-117]. The latter observation is in contrast to knock-
down experiments using siRNAs directed against APH-1 and 
NCT which trigger reduced formation of PS heterodimers 
without the stable accumulation of PS-holoprotein observed 
in cells with down-regulated PEN-2 [17, 88, 116, 117]. This 
supports a critical function of PEN-2 in the endoproteolysis 
of PS-holoprotein and the maturation of the complex. 
Moreover, the accumulation of iNCT in cells with down-
regulated PEN-2 supports a direct interaction of PEN-2 with 
the trimeric iNCT/APH-1/PS-holoprotein subcomplex in the 
ER/cis-Golgi compartments [116]. Next, the overexpression 
of PEN-2 in different cell lines facilitates PS-holoprotein 
endoproteolysis [17, 116]. Also, PEN-2 preferentially binds 
both PS-holoprotein and mNCT in our experiments, suggest-
ing that this component binds to the complex at a later stage 
of assembly and plays a critical role in the endoproteolysis of 
PS [117]. In support to this, we found that in cells stably 
overexpressing only PS1 and Flag-PEN-2, antibodies di-
rected to the very C-terminus of PS1-CTF (this domain is 
inaccessible to those antibodies when folded into the active 
complex) could co-IP PEN-2 and anti-Flag antibodies 
brought down full-length PS1 [48]. This observation demon-
strates that PEN-2 can associate with full-length PS1 in a 
manner independent of NCT, APH-1, and PS1-NTF, sug-
gesting that PEN-2 and PS1-holoprotein are capable of inter-
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acting physically with each other. The detergent-dependent 
dissociation of active ?-secretase further revealed an interac-
tion between PEN-2 and PS1-CTF [48]. Finally, the prefer-
ential association of PEN-2 with mNCT supports a critical 
role for PEN-2 in a late stage during the assembly of ?-
secretase. Indeed, we recently developed protocols for the 
high-grade purification of proteolytically active ?-secretase 
[21, 128]. As a last step of purification, we developed an M2 
anti-Flag antibody immuno-affinity procedure, a separation 
based on the presence of Flag-PEN-2 in the active complex 
[21, 128]. We found that mNCT and PS1 heterodimers (PS1-
NTF & PS1-CTF) were enriched after the M2 anti-Flag anti-
body immuno-affinity purification of Flag-PEN-2, further 






















Fig. (3). Schematic representation of the assembly and activation in the secretory pathway of the ?-secretase complex. The assembly 
of the ?-secretase complex involves the early formation in the ER of an intermediate subcomplex of APH-1 and the “immature” N-linked 
isoform of NCT (iNCT) that is not associated with active ?-secretase (= iNCT/APH-1 subcomplex). PS-holoprotein then binds to the 
iNCT/APH-1 subcomplex to form a second trimeric intermediate (= iNCT/APH-1/PS-holoprotein subcomplex). In this trimeric intermediate, 
PS-holoprotein likely adopts a conformation in which the hydrophobic domain that contains the site of PS-holoprotein endoproteolysis is 
membrane-embedded in a close proximity to TMD6 and TMD7, with the consequence of occluding the active site. The association of PEN-2 
in the ER/cis-Golgi compartments to the trimeric and inactive iNCT/APH-1/PS-holoprotein subcomplex triggers a conformational change (in 
PS-holoprotein?) that promotes (1) the endoproteolytic cleavage of PS-holoprotein and subsequently (2) the activation and trafficking of ?-
secretase, with (3) the conversion from an immature to a mature form of NCT (mNCT) with a different and more complex glycosylation 
pattern. The fully matured and active ?-secretase (mNCT/APH-1/PS-NTF/PS-CTF/PEN-2) is mainly localized in different cell compartments 
including the Golgi, the trans-Golgi network (TGN), the endosomes, the lysosomes and the plasma membrane.  
3D Structure of ?-Secretase Current Genomics, 2007, Vol. 8, No. 8    541 
PS heterodimers are associated with the active ?-secretase 
complex [80, 81, 129]. 
4. The mNCT/APH-1/PS-NTF/PS-CTF/PEN-2 Active 
Complex 
When taken together, the results described above strong- 
ly support a model in which PEN-2 is added to the trimeric 
iNCT/APH-1/PS-holoprotein subcomplex in the ER/cis-
Golgi compartments and promotes the trafficking and activa-
tion of ?-secretase. The fully matured and active ?-secretase 
(mNCT/APH-1/PS-NTF/PS-CTF/PEN-2) has been reported 
to be mainly localized in cell compartments including the 
Golgi [130-132], trans-Golgi network (TGN) [131, 133], 
endosomes [133-135], lysosomes [136-138], and plasma 
membrane [134, 135, 139-143].  
Three-Dimensional Structure of the ?-Secretase Complex 
?-Secretase is the founding member of an emerging class 
of intramembrane-cleaving proteases (I-CliPs) that includes 
site 2 protease (S2P), Rhomboids and signal peptide pepti-
dase (SPP) (for a review, see [144]). Like ?-secretase, S2P, 
Rhomboid, and SPP all hydrolyze their respective substrates 
within their TM regions, and the residues responsible for 
catalysis are either intramembranous or at the predicted 
membrane-cytosol interfaces of the proteases. Rhomboid and 
SPP function as a single component that can be overex-
pressed and purified from bacteria with catalytic activity 
[145, 146] and in amounts adequate for crystallization stud-
ies [26-28, 147]. In sharp contrast, ?-secretase is a multi-
component protease with complex assembly, maturation 
(including N-linked glycosylation of NCT, a post-transla- 
tional modification that does not occur in prokaryotic sys-
tems) and activation processes. It is thus likely that prokary-
otic systems are not appropriate for the overexpression of 
physiological ?-secretase for crystallization studies. Indeed, 
?-secretase has never been overexpressed in an active form 
in bacteria and the PS endoproteolytic event, which has been 
associated with the biological activity of ?-secretase, has 
never been reproduced in prokaryotic systems. However, 
proteolytically active ?-secretase has been reconstituted in S. 
cerevisiae which lacks this enzyme [20]. Nevertheless, only 
a small fraction of the overexpressed PS holoprotein was 
endoproteolysed into active NTF- and CTF fragments [20], 
suggesting that the yeast system is currently unsuitable for 
the production of large quantities of purified complexes for 
structural studies. Functional ?-secretase has also been re-
constituted in the baculovirus/insect cell system by co-
infecting all four components (His/Flag-PS1, NCT-V5/His, 
APH-1-myc/His, and PEN-2) into Spodoptera frugiperda 
Sf9 cells [148]. This system was used to develop a three-step 
procedure (anti-FLAG immunoaffinity chromatography, size 
exclusion chromatography and Ni-NTA affinity chromatog-
raphy) for the purification of active ?-secretase [149]. To 
assess the 3-dimensional structure of ?-secretase, we devel-
oped a specific and reproducible protocol for the high-grade 
purification of intact, proteolytically active ?-secretase com-
plexes from Chinese hamster ovary (CHO) cells that stably 
overexpress human PS1, APH-1-HA and Flag-PEN-2 in the 
presence of high levels of endogenous NCT (designated ?-30 
cells) [21].  
1. A Water-Containing Chamber in the Catalytic Core of ? -
Secretase Provides the Hydrophilic Environment Required 
for Proteolysis 
Electron microscopy (EM) and single particle image 
analysis of ?-secretase purified from the ?-30 CHO cells 
were used to determine the first three-dimensional structure 
of ?-secretase at a resolution of 15 A° [22]. First, EM re-
vealed ?-secretase particles that measured 80-100 Å in di-
ameter, consistent with particles of ~300 kDa in mass, a size 
that has been reported using biochemical sizing methods, 
including BN-PAGE [21, 48, 117]. Next, a total of 12,000 
individual particle images were used to generate the refined 
3D reconstruction [22]. Purified, active ?-secretase was 
found to have an elongated globular structure, with the larg-
est dimension being ~120Å and the other two dimensions 
perpendicular to the long axis being about 70-80 Å each 
[22]. The most dramatic feature of the structure was the 
presence of a low-density central (and possibly water-con- 
taining) intramembrane chamber with a diameter of 20-40 Å 
(see the cut-open view displayed in Fig. (4); [22]). In a dif-
ferent but very similar study, EM and analysis of 2341 nega-
tively stained ?-secretase particles purified from the bacu-
lovirus/insect cell system resulted in the 3D-representation 
of ?-secretase at a resolution of 48 Å [149]. Supporting the 
possible existence of a water-containing chamber, the recon-
struction of the ?-secretase complex purified from the bacu-
lovirus/insect cell system revealed an elongated structure 
with a large pore in the center [149]. Experimental and bio-
chemical evidence for the existence of a water-filled cavity 
in the intramembranous part of ?-secretase has been provided 
by using a cysteine-scanning mutagenesis approach [150, 
151]. The principle involves substitution of amino-acid resi-
dues of interest with cysteine and the use of membrane-per- 
meable or –impermeable sulfhydryl-directed reagents. Cys-
teines embedded in the membrane, unless exposed to a wa-
ter-containing cavity, are not reactive with such reagents. 
Taking advantage of the unique properties of cysteine-
scanning mutagenesis, Tolia et al. found that cysteines intro-
duced at several positions in TMD 6 and TMD7 of PS1 (in-
cluding the catalytic Asp-385) were accessible to N-[6-(bio- 
tinamido)hexyl]– 3’-(2’-pyridyldithio)-propionamide (EZ-
link biotin-HPDP), a sulfhydryl-specific reagent, implying 
that these residues have access to water within the lipid bi-
layer [150]. The authors also propose that Y389 of PS1 is 
involved in the catalytic mechanism through the formation of 
a hydrogen bond with the side chain of D385 and found that 
the membrane-permeable and biotinylated sulfhydryl-speci- 
fic cross-linker did not label D257C (inaccessible to water?), 
whereas a homobifunctional sulfhydryl-specific cross-linker 
did target both D257C and D385C (both accessible to water) 
[150]. A model is proposed to explain this apparent discrep-
ancy, based on functionally distinct complexes. This model 
suggests that D257 of PS1 remains inaccessible to water in 
inactive ?-secretase, but does get access to water during hy-
drolysis in active ?-secretase, possibly upon conformational 
modulations within TMD6 initiated after binding of the sub-
strates. In a similar study, Sato et al. further demonstrated 
that TMD6 and TMD7 of PS1 contribute to the formation of 
a hydrophilic pore within the membrane [151]. When taken 
together, these results provide biochemical evidence for the  
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existence of a water-filled cavity in the catalytic core of ?-
secretase. While the requirement for water molecules to ac-
complish peptide bond hydrolysis is expected, it represents 
the first experimental evidence that the catalytic aspartic 
residues are both accessible to water and face each other 
with a maximal distance of 5.2 Å. 
2. A Model for the Intramembrane Processing of Mem-
brane Proteins by ?-Secretase  
Our structural analysis of the purified ?-secretase com-
plex further revealed an extracellular density at the top of the 
map which can be attributed to a part of the large (669 amino 
acid) ectodomain of NCT, as it comprises a long extracellu-
lar polypeptide (~70 kDa) onto which N-linked oligosaccha-
ride groups are attached (Fig. (4); [22]). Moreover, two addi-
tional openings to the interior chamber were observed: one 
of ~20 Å size (designated H1) facing up towards the exterior 
of the cell, and the other about 10 Å in size (designated H2) 
facing down towards the cytoplasm (Fig. (4); [22]). Finally, 
two weak density regions (asterisks in Fig. (4)) were also 
observed on the attributed intramembrane surface [22].  
When taken together, this 3D structure of ?-secretase 
provides plausible explanations for certain long-standing 
questions. Indeed, the most enigmatic feature of ?-secretase 
and other intramembrane proteases is their location within 
the hydrophobic environment of the membrane and yet their 
requirement for water molecules to accomplish peptide bond 
hydrolysis. How ?-secretase releases its two cleavage prod-
ucts into distinct subcellular compartments has also been 
mysterious. The 3D structure of ?-secretase and the structural 
details described above offer a model for the intramembrane 
processing of membrane proteins as depicted in Fig. (5A). In 
this model, the observed interior chamber and apical and 
basal pores would allow the entry of water molecules and 
their sequestration from the lipid surround by the proteina-
ceous microenvironment provided by the many transmem-
brane domains. The two thin-density regions in the trans-
membrane portion (labeled with stars in Fig. (4)) may repre-
sent sites which could be transiently opened up to enable 
entrance of the ?-helically conformed substrates, i.e., the 
TMDs of various single transmembrane proteins. After a 
substrate (e.g., C99 of APP or the analogous N?E fragment 
of Notch) enters the proteinaceous central chamber and un-
dergoes hydrolysis by the 2-aspartate-containing catalytic 
site in PS, the cleavage product that includes the extracellu-
lar half of the substrate’s TMD (e.g., A? or Np3) could be 
released through the H1 channel to the extracellular surface, 
and the product that includes the cytoplasmic half of the sub-
strate’s TMD plus the intracellular region (e.g., AICD or 
NICD) could be released through the H2 channel to the cy-
toplasm (Fig. (5A)). 
3. Crystal Structure of GlpG, an E. coli Intramembrane 
Protease of the Rhomboid Family: A Model for ? -
Secretase? 
Despite the recent progress, the low-resolution 3D struc-
tures of ?-secretase failed to answer some important ques-
tions. First, the stoichiometry and spatial organization of the 
complex are still under debate, with the number of PS mole-
cules at the catalytic site of the complex being controversial. 
Indeed, evidence suggests that two PS molecules (a dimer) 
are at the catalytic core of a single protease complex [152-
156]. In sharp contrast to this hypothesis, co-IP and western 
blot methods concluded that the ?-secretase complex con-
tains only one copy of each component, demonstrating that 
the stoichiometry of the active mNCT/APH-1/PS-NTF/PS-









Fig. (4). Three-dimensional structure of ?-secretase and GlpG, an E. coli intramembrane protease of the Rhomboid family. (A) Elec-
tron microscopic three-dimensional representation of the ?-secretase complex at a resolution of 15 Å. Left: The potential transmembrane 
segment with the belt-like structure (blue) is outlined by two parallel dashed lines, 60 Å apart, representing the membrane bilayer. The NCT 
ectodomain is located at the top density region as confirmed by lectin binding experiments. Right: A cut-open view of the complex from the 
side reveals a large central chamber of 20-40 Å in length, one opening (H1, 20 Å) facing the extracellular region and one opening facing the 
cytosolic region (H2, 20 Å). Two weak density regions are labeled with stars. Figure modified from [22] with permission (copyright National 
Academy of Sciences, USA). (B) Crystal structure of GlpG a bacterial rhomboid, in an open conformation and at a resolution of 2.6 Å. The 
putative catalytic-dyad Ser 201 and His 254 residues are shown in red. The water molecules (orange spheres) required to accomplish peptide 
bond hydrolysis may enter the membrane-embedded active sites by different routes from the outside (and/or inside?) aqueous solution, in-
cluding the central chamber (GlpG) and the H1 and/or H2 pores (?-secretase). Figure modified from [27] with permission. 
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unpublished). Next, how the catalytic site of ?-secretase is 
organized remains unknown. There is little ambiguity about 
the peptide bond scission being carried out by two aspartates 
in PS, but the locations of the active site and the oxyanion-
binding site (that stabilizes the negative charge developed on 
the carbonyl oxygen of the scissile bond during catalysis) are 
not yet defined. Moreover, the molecular mechanisms ex-
plaining the access of the substrates to the catalytic site re-
main largely unknown. How is this access regulated? Do 
protease plasticity and substrate binding support a gate-
opening mechanism as described for the GlpG rhomboid 
protease (four crystal structures ranging in resolution from 
2.1 to 2.6 Å have been obtained almost simultaneously by 
three different laboratories [26-28, 147])? The 2.1 Å resolu-
tion crystal structure of a truncated but proteolytically active 
version of the E. coli GlpG rhomboid protease (named GlpG 
core domain) provided the first atomic-scale representation 
of an intramembrane protease [26]. While the requirement 
for water to accomplish peptide bond hydrolysis is expected, 
Wang et al. provide the first experimental evidence that the 
active site found in a central cavity that contains all the con-
















Fig. (5). Possible mechanisms of ?-secretase and GlpG rhomboid-catalyzed intramembrane proteolysis. (A) Model for the ?-secretase 
dependent intramembrane processing of membrane proteins. In this model, the observed interior chamber and apical and basal pores (H1 and 
H2, respectively) would allow the entry of water molecules and their sequestration from the lipid surround by the proteinaceous microenvi-
ronment provided by the many transmembrane domains. The two thin-density regions in the transmembrane portion (labeled with green 
stars) may represent sites which could be opened up transiently (lateral gate-opening mechanism?) to enable entrance of the ?-helically con-
formed substrates, i.e., the TMDs of various single transmembrane proteins (step I = substrate binding). After a substrate including APP-C-
terminal fragments of APP (APP-C99 and APP-C83 with APP-C99 being only represented here) enters the water-filled central chamber, it 
undergoes hydrolysis by the two aspartate-containing catalytic site (red star) in PS (step II = substrate entrance/cleavage). The cleavage 
products that include the extracellular half of the substrate’s TMD (A?) could then be released through the H1 channel to the extracellular 
surface, whereas the product that includes the cytoplasmic half of the substrate’s TMD plus the C-terminal-intracellular domain (AICD for 
APP-IntraCellular Domain) could be released through the H2 channel to the cytoplasm (step III = products release). This possible mecha-
nism further offers an explanation about how ?-secretase releases its two cleavage products into distinct subcellular compartments. (B) Side 
(left) and top (right) views of GlpG in an open cap conformation. The transmembrane helices are shown as cylinders labeled 1-6. A mem-
brane-embedded loop structure (called L5 cap) is intrinsically flexible, consistent with the expectation that it can be displayed by the sub-
strates, thus promoting the passage between TMD5 and TMD2 and active site access (proposed lateral substrate gate). The catalytic Ser 201 
and His 254 residues are highlighted in red. Figure modified from [147] with permission (copyright National Academy of Sciences, USA). 
(C) A model for the interaction of substrates with GlpG (side view). TMD5 and TMD2 regions may represent sites which could be opened 
up transiently (lateral gate-opening mechanism) to enable entrance into the active site cavity of the ?-helically conformed membrane sub-
strate (straight or tilted) with the cleavage site being represented in a non-helical and accessible conformation that favors the proteolytic 
processing. Figure modified from [28] with permission (copyright National Academy of Sciences, USA). 
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accepts a number of water molecules [26]. Interestingly, a 
large V-shaped opening between two transmembrane helices 
(S1 and S3 in TMD1 and TMD3, respectively) and facing 
laterally towards the lipid is proposed to be the route (sub-
strate docking site? Substrate binding site?) by which a sub-
strate enters the active site [26]. Importantly, the crystal 
structure described in this report (and resolved in the absence 
of any substrate) shows that this lateral opening is blocked 
by a membrane-embedded loop structure (called L1). The 
authors postulate that L1 functions as a “lateral gate”, which 
may control substrate access to the active site. In contrast, 
the structures of GlpG reported by Wu et al. [27] and Ben-
Shem et al. [28] lead to a structural model for gating in 
which TMD5 moves away from the catalytic site, carrying 
the L5 loop with it, to provide active site access for sub-
strates passing between TMD5 and TMD2. By describing a 
new crystal structure of GlpG in a more open conformation, 
Wang and Ha demonstrated that L5 is indeed intrinsically 
flexible, consistent with the expectation that this loop can be 
displaced by the substrates in the “open-cap” state [147]. In a 
structure-function approach analyzing engineered GlpG vari-
ants, Baker et al. further implicated the helix in TMD5 as the 
lateral substrate gate [158]. Both studies further support the 
model first proposed by Wu et al. and Ben-Shem et al. in 
which the membrane substrates may enter the protease active 
site through the gap between TMD2 and TMD5 (Fig. (5B & 
C)). When taken together, the proposed gating mechanisms 
for the substrate access to the GlpG catalytic site are consis-
tent with the model proposed by Brunkan et al. in which the 
membrane-embedded domain that contains the presenilin 
(PS) endoproteolysis site controls substrate access to the 
catalytic aspartates of ?-secretase by occluding the active site 
[56]. However, a major difference lies on the observation 
that ?-secretase activity depends on the processing of full-
length PS (FL-PS) into PS-NTF and PS-CTF domains (re-
sulting in the accessibility for the substrates to the active 
site), whereas the rhomboid L5 loop does not require this 
additional maturation step.  
Despite some important functional similarities, ?-secre- 
tase probably uses different and additional structural motifs 
to accomplish substrate selectivity and intramembrane prote-
olysis. For example, the NCT large extracellular domain has 
recently been shown to be essential for recognition of sub-
strates by the ?-secretase complex [19]. The structure (and 
sequence) of GlpG does not display such a similar domain. 
Next, the 3D electron microscopic structure of the purified, 
proteolytically active ?-secretase, revealed that the NCT ec-
todomain covers the top of the large aqueous intramembrane 
chamber, suggesting a role as a type of flexible lid that could 
regulate (1) the entry of water molecules into the central 
chamber and/or (2) the exit of hydrophilic ectodomain prod-
ucts [22]. When taken together, it seems unlikely (but can 
not yet be excluded) that the short loop (L5) which tightly 
caps the GlpG active site from above fulfills similar func-
tions. Co-crystallization of the GlpG core domain with a 
recombinant substrate would certainly provide a structural 
explanation for how a substrate can modulate the conforma-
tion of the proposed lateral gate, providing a good starting 
model for how substrates can be differentially handled in the 
catalytic site of ?-secretase.  
Finally, ?-secretase, site-2 protease (S2P), or the signal 
peptide peptidase (SPP) are unrelated to rhomboids by se-
quence or evolution - another major difference comes with 
the observation that ?-secretase only cleaves type-I mem-
brane proteins whereas SPP only cleaves type-II membrane 
proteins. Awaited high-resolution structures of S2P, SPP and 
?-secretase will solve the mystery of how they are similar 
and different. 
ACKNOWLEDGEMENTS 
P.C.F. thanks the Swiss National Science Foundation 
(Grant 310000-116652/1), the NCCR “Neural Plasticity and 
Repair”, the Novartis Foundation for Medicine and Biology, 
and the Swiss Academy of Medical Sciences for supporting 
research in his laboratory. P.C.F. also thanks the members of 
his laboratory for critical comments on the manuscript, Y. 
Shi, Y. Ha, E. Bibi and H. Li for providing original figures, 
and apologizes to the many investigators whose contribu-
tions have not been mentioned or cited owing to space re-
strictions.  
ABBREVIATIONS 
A? = Amyloid-? protein 
AD = Alzheimer’s disease 
APP = amyloid-? precursor protein 
AICD = APP intracellular domain 
CHO = Chinese hamster ovary 
CTF = C-terminal fragment 
ER = Endoplasmic reticulum 
FAD = Familial Alzheimer’s disease 
HMW = High molecular weight 
IP = Immunoprecipitation 
kDa = kiloDalton 
NCT = Nicastrin 
NTF = N-terminal fragment 
PS = Presenilin 
TACE = Tumor necrosis factor ? (TNF-?)-converting 
enzyme 
TGN = Trans-Golgi network 
TM = Transmembrane 
TMD = Transmembrane domain 
WT = Wild-type 
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